List of Excipients in Branded Drug NOCDURNA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Antares Pharma Inc	NOCDURNA	desmopressin acetate	54436-325	ANHYDROUS CITRIC ACID
Antares Pharma Inc	NOCDURNA	desmopressin acetate	54436-325	MANNITOL
Antares Pharma Inc	NOCDURNA	desmopressin acetate	54436-325	MARINE NON-GELLING GELATIN, HIGH MW
Ferring Pharmaceuticals Inc	NOCDURNA	desmopressin acetate	55566-5050	ANHYDROUS CITRIC ACID
Ferring Pharmaceuticals Inc	NOCDURNA	desmopressin acetate	55566-5050	MANNITOL

Nocdurna Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Nocdurna is a low-dose sublingual desmopressin acetate product developed by Ferring Pharmaceuticals for nocturia caused by nocturnal polyuria in adults. Its formulation uses gelatin, mannitol, and citric acid in a rapidly disintegrating oral dosage form. The principal commercial opportunity is not a new desmopressin molecule. It is a differentiated delivery system that improves dose uniformity, taste, moisture stability, patient acceptability, and manufacturing economics while preserving the rapid, water-free administration profile. [1]

What is Nocdurna and how does its formulation work?

Nocdurna is supplied in two strengths:

Product	Desmopressin acetate	Desmopressin equivalent	Administration
Nocdurna 25 mcg	27.7 mcg	25 mcg	Sublingual
Nocdurna 50 mcg	55.3 mcg	50 mcg	Sublingual

The tablet is placed under the tongue without water. Patients are instructed to avoid eating or drinking from one hour before administration until eight hours afterward. This dosing design supports nighttime use, when conventional tablets requiring water may be less convenient. [1]

Nocdurna’s approved indication is nocturia due to nocturnal polyuria in adults who awaken at least twice per night to urinate. The product is not interchangeable with all other desmopressin formulations because dose, route, absorption, and safety controls differ.

What excipients are used in Nocdurna?

The U.S. prescribing information identifies the inactive ingredients as:

• Gelatin
• Mannitol
• Citric acid

The label does not assign a separate functional role to each excipient. Based on sublingual tablet design and common formulation practice, the likely roles are:

Excipient	Likely formulation role	Commercial significance
Gelatin	Matrix former, binder, structural support for a rapidly disintegrating tablet	Enables fast breakup but creates animal-origin and moisture-management issues
Mannitol	Bulking agent, filler, mouthfeel modifier	Provides a cooling sensation and supports low-dose tablet manufacture
Citric acid	Acidulant, pH modifier, taste adjustment	Can improve palatability and influence local dissolution conditions

Because the active dose is measured in micrograms, excipient selection is closely tied to content uniformity. Small variations in blend homogeneity, particle size, or compression behavior can materially affect dose accuracy.

What excipient strategy gives Nocdurna its commercial profile?

The formulation strategy has four commercial objectives: rapid disintegration, acceptable taste, low-dose uniformity, and administration without water.

Rapid disintegration

A sublingual tablet must break apart quickly in a small volume of saliva. Conventional high-hardness tablets may delay drug release. A suitable excipient system must provide adequate mechanical strength during packaging and handling while maintaining rapid wetting and disintegration in the mouth.

Mannitol is commercially attractive because it has good mouthfeel and can support orally disintegrating and sublingual dosage forms. Its relatively low hygroscopicity compared with some alternative polyols can also help tablet stability.

Taste and mouthfeel

Desmopressin products require prolonged patient adherence because nocturia treatment is typically chronic. Bitter or metallic taste can reduce persistence. Mannitol may reduce perceived bitterness through sweetness and cooling. Citric acid can alter salivary pH and improve the overall flavor profile, although excess acidity may produce irritation.

Taste masking is a potential improvement area. Options include:

• Ion-exchange resins
• Polymer-coated drug particles
• Cyclodextrin complexes
• Lipid-based taste barriers
• pH-modifying microenvironments
• Co-processed mannitol systems

Each approach must be assessed against the need for rapid sublingual release. A taste-masking layer that delays dissolution could undermine the product’s pharmacokinetic profile.

Low-dose content uniformity

Nocdurna has a particularly demanding dose-uniformity problem because the active quantity is very small relative to total tablet mass. Commercially viable alternatives may use:

• Ordered mixing
• Spray-dried active-excipient intermediates
• Carrier-based drug layering
• Continuous blending with real-time monitoring
• Segregation-resistant co-processed excipients

The most defensible manufacturing advantage would come from a process that improves uniformity without increasing tablet weight or production complexity.

Moisture control

Sublingual tablets are vulnerable to moisture during manufacturing, storage, and removal from packaging. Moisture can alter tablet strength, disintegration, chemical stability, and package performance.

Unit-dose aluminum blister packaging is therefore commercially important. A formulation that maintains stability in lower-cost high-barrier packaging could create a meaningful margin advantage. A moisture-tolerant, gelatin-free formulation would have further value for global commercialization.

What formulation patents could protect Nocdurna or a competing product?

The relevant intellectual-property categories are broader than the active ingredient:

Patent category	Potentially protectable subject matter	Commercial effect
Composition	Sublingual desmopressin with specific excipient ratios	Can delay direct formulation substitution
Dosage form	Rapidly disintegrating or freeze-dried tablet structure	Protects delivery architecture
Method of manufacture	Mixing, granulation, drying, compression, or lyophilization process	Raises manufacturing-copying barriers
Packaging	Moisture-protective blister and dose-protection systems	Can support stability and shelf-life claims
Method of use	Low-dose desmopressin for nocturnal polyuria with fluid restriction	May support use-based enforcement
Pharmacokinetic profile	Rapid absorption or defined exposure parameters	Can complicate bioequivalence design

The original desmopressin compound is old and does not provide a meaningful new-molecule exclusivity barrier. The commercial protection for Nocdurna therefore depends on formulation, dosage-form, manufacturing, regulatory exclusivity, trademarks, and clinical positioning.

A current Orange Book review is required to establish the complete list of listed patents, patent-use codes, and expiration dates. The FDA prescribing information identifies the product and approved use but does not provide a complete patent table. [1,2]

When does Nocdurna lose exclusivity?

Nocdurna received FDA approval in 2018. The product’s initial U.S. regulatory protection included new-drug exclusivity associated with the approval, but that period is no longer the principal barrier to generic competition. Generic entry now depends mainly on:

1. Listed patents and their remaining enforceable terms.
2. The ability to demonstrate bioequivalence for the sublingual dosage form.
3. The scope of any method-of-use patents.
4. FDA requirements for labeling, dosing, and hyponatremia risk management.
5. Manufacturing capability for microgram-dose content uniformity.

For a standard abbreviated new drug application, a competitor may pursue Paragraph III certification if it accepts delayed entry until patent expiry, or Paragraph IV certification if it asserts that listed patents are invalid, unenforceable, or not infringed. A Paragraph IV filing can trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework. [3]

The relevant patent-expiration dates should not be inferred from the 2018 approval date. Formulation and use patents may have different terms, patent-term adjustments, pediatric extensions, or terminal disclaimers.

What FDA regulatory barriers affect generic Nocdurna?

The key regulatory challenge is demonstrating equivalence for a sublingual product rather than simply matching tablet strength.

Bioequivalence

A generic applicant must address:

• Dose strength and desmopressin equivalence
• Sublingual administration
• Early exposure and absorption rate
• Total systemic exposure
• Tablet disintegration and dissolution
• Food and fluid restrictions
• Dose uniformity
• Stability after package opening or handling

FDA may accept an ANDA pathway if the product can meet applicable sameness and bioequivalence requirements. A materially different delivery system could instead require a 505(b)(2) application, particularly if it changes the route, release profile, dosing schedule, or clinical use. [3]

Safety labeling

Nocdurna carries a boxed warning for severe hyponatremia. The label requires serum sodium assessment before treatment, within the first week, approximately one month after initiation, and periodically thereafter. Patients with certain risk factors, including excessive fluid intake, renal impairment, and uncontrolled hypertension, require particular attention. [1]

An excipient change cannot remove this central safety risk. A competitor may improve usability, taste, and stability, but it must preserve the same core fluid-restriction and sodium-monitoring framework unless it generates new clinical evidence.

What commercial opportunities exist for Nocdurna excipient innovation?

Gelatin-free sublingual tablets

A gelatin-free product could address vegetarian, religious, cultural, and animal-origin concerns. Potential replacements include:

• Pullulan
• Hydroxypropyl methylcellulose
• Polyvinyl alcohol
• Crospovidone-based direct-compression systems
• Plant-derived polysaccharide matrices

The main technical requirement is matching gelatin’s structural and disintegration performance without increasing moisture sensitivity or tablet friability.

Improved taste-masked formulations

Taste masking is commercially relevant for patients who hold the tablet under the tongue. A formulation with lower bitterness and less acidity could support adherence and brand differentiation.

Moisture-resistant packaging and formulation

A product with better resistance to humidity could reduce packaging cost, simplify distribution in hot and humid markets, and reduce stability failures. Packaging patents may provide protection even when the excipient composition is difficult to defend.

Lower-cost generic manufacture

Generic manufacturers can pursue a cost advantage through direct compression, continuous manufacturing, reduced excipient count, and automated in-process control. The commercial prize is a high-value niche with fewer potential competitors than conventional oral desmopressin tablets.

Alternative dosage forms

Potential follow-on products include:

• Orally disintegrating tablets
• Mucoadhesive buccal films
• Sublingual films
• Unit-dose oral powders
• Pediatric-compatible liquid or dispersible systems

These products may have a stronger 505(b)(2) profile than an ANDA if they materially change delivery or patient population. Pediatric development is commercially constrained by desmopressin-associated hyponatremia risk and would require a separate regulatory and clinical strategy.

How does Nocdurna compare with conventional desmopressin products?

Attribute	Nocdurna	Conventional oral desmopressin tablet	Nasal desmopressin
Route	Sublingual	Oral	Intranasal
Water required	No	Usually yes	No
Primary use	Adult nocturnal polyuria	Multiple desmopressin indications depending on product	Multiple indications depending on product
Excipient challenge	Rapid dissolution and taste	Conventional tablet performance	Spray stability and device delivery
Dose flexibility	Limited approved strengths	Product-dependent	Device-dependent
Main safety issue	Hyponatremia	Hyponatremia	Hyponatremia and administration variability

Nocdurna’s differentiation is convenience and low-dose sublingual delivery. Its weakness is a narrow indication, a boxed hyponatremia warning, and the need for strict fluid restriction.

Which companies are positioned to challenge Nocdurna?

The competitive field includes:

• Generic manufacturers with existing desmopressin capabilities
• Specialty pharmaceutical companies developing orally disintegrating products
• Drug-delivery companies focused on sublingual films or buccal systems
• Contract development and manufacturing organizations with lyophilized-tablet platforms

The strongest challengers will likely have experience with microdose blending, orally disintegrating dosage forms, high-barrier blister packaging, and FDA bioequivalence programs. Traditional tablet manufacturers may have the active ingredient capability but face greater risk in reproducing the sublingual performance profile.

What patent litigation and settlement risks affect Nocdurna?

The main litigation scenarios are:

1. A Paragraph IV challenge to a formulation or method-of-use patent.
2. A dispute over whether the generic product falls within a listed patent claim.
3. Litigation over bioequivalence or the proper regulatory pathway.
4. A settlement providing an agreed generic entry date.
5. A dispute over patent listing or delisting in the Orange Book.

No settlement date or generic launch date should be assumed from the FDA approval history alone. Any commercial forecast should separate a tentative launch based on patent expiry from an earlier launch based on litigation settlement or successful invalidity litigation.

What is the revenue exposure and market opportunity?

Nocdurna addresses adults with clinically significant nocturia, but the addressable market is restricted by diagnosis, contraindications, fluid-management requirements, sodium monitoring, and physician willingness to prescribe desmopressin.

Commercial upside is strongest in:

• Urology and urogynecology
• Older adults with nocturnal polyuria
• Patients seeking a water-free nighttime dosage form
• Markets where sleep disruption has a high treatment burden
• Generic opportunities where competing desmopressin products do not replicate the same administration profile

Revenue exposure is more sensitive to generic formulation success than to new indication expansion. A single technically credible ANDA could pressure price if it matches the sublingual profile. A differentiated gelatin-free, taste-masked, or moisture-stable product could preserve premium pricing through a 505(b)(2) pathway or branded lifecycle strategy.

Key Takeaways

• Nocdurna uses gelatin, mannitol, and citric acid in a sublingual desmopressin tablet.
• The formulation’s commercial value comes from water-free administration, rapid dissolution, taste, and low-dose uniformity.
• Mannitol and citric acid support mouthfeel and palatability; gelatin creates a potential target for animal-origin and moisture-stability improvements.
• The active molecule is old, so formulation, manufacturing, regulatory, and clinical-use patents carry most of the strategic value.
• Generic entry will depend on sublingual bioequivalence, microgram-dose content uniformity, packaging stability, and any listed patent barriers.
• Gelatin-free tablets, improved taste masking, moisture-resistant packaging, and lower-cost manufacturing are the clearest excipient-driven opportunities.
• Hyponatremia remains the central safety constraint and cannot be solved through excipient selection alone.

FAQs

Can Nocdurna be reformulated with mannitol alternatives?

Yes. Lactitol, sorbitol, xylitol, isomalt, and co-processed polyol systems are potential alternatives, but each must be evaluated for hygroscopicity, mouthfeel, compression, dissolution, and dose uniformity.

Is gelatin in Nocdurna a regulatory barrier?

Gelatin is not inherently a regulatory barrier, but its source, quality attributes, animal-origin documentation, and moisture behavior can affect global commercialization and patient acceptance.

Could a sublingual desmopressin film replace Nocdurna?

A sublingual film could provide a differentiated product, but it would require evidence for dose uniformity, adhesion, mucosal delivery, stability, and comparative exposure. The regulatory pathway could differ from a conventional ANDA.

Can an excipient change reduce Nocdurna’s hyponatremia risk?

Not reliably. Hyponatremia is primarily linked to desmopressin pharmacology, dose, patient selection, renal function, and fluid intake. An excipient change would not remove the boxed-warning requirements without substantial clinical evidence.

What is the strongest generic development strategy for Nocdurna?

The strongest strategy combines a formulation that matches rapid sublingual performance with robust microdose content uniformity, moisture-protective packaging, conservative bioequivalence planning, and a clear analysis of Orange Book patents and use codes.

References

1. U.S. Food and Drug Administration. (2018). Nocdurna (desmopressin acetate) sublingual tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2018). Nocdurna approval letter.
3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.